Sep. 09 2024
Source Page: Communications regarding cancer strategy: FOI ReviewFound: Communications regarding cancer strategy: FOI Review
Sep. 09 2024
Source Page: Communications regarding cancer strategy: FOI ReviewFound: Communications regarding cancer strategy: FOI Review
Asked by: Stephen Timms (Labour - East Ham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to improve pancreatic cancer outcomes in East Ham constituency.
Answered by Andrew Stephenson
NHS England is delivering a range of interventions that are expected to increase early diagnosis and improve outcomes for those with pancreatic cancer across England, including the East Ham constituency. This includes: providing a route into pancreatic cancer surveillance for those at inherited high-risk to identify lesions before they develop into cancer and diagnose cancers sooner; creating new pathways to support faster referral routes for people with non-specific symptoms that could be linked to a range of cancer types; and increasing direct access for general practitioners to diagnostic tests.
To increase early diagnosis, NHS England are implementing non-symptom specific pathways (NSS) for patients who present with non-specific symptoms, or combinations of non-specific symptoms, to receive the right tests at the right time. There are currently 113 NSS pathways live with the aim to have full national coverage by 2025.
NHS England is also funding a new audit into pancreatic cancer, the aim of which is to provide regular and timely evidence to cancer service providers of where patterns of care in England may vary, to increase the consistency of access to treatments and to stimulate improvements in cancer treatment and outcomes for patients. The Royal College of Surgeons began work on this audit in October 2022 and a scoping exercise in consultation with key stakeholders has taken place to shape the direction of the audit. The first report is expected in October 2024.
In addition, the Getting It Right First Time team in NHS England is undertaking a deep dive into pancreatic cancer, which will highlight actions National Health Service providers need to take to improve services, as well as gathering examples of good practice to share.
Asked by: Victoria Collins (Liberal Democrat - Harpenden and Berkhamsted)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, whether he has had discussions with the Secretary of State for Health and Social Care on the development of (a) a breath test to identify pancreatic cancer and (b) technologies to aid early detection of all cancers.
Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
The project to develop a breath test to identify pancreatic cancer is funded via the NIHR i4i/OLS: Early Cancer Diagnosis Clinical Validation and Evaluation Call. This £11 million programme funds 6 projects that aim to develop technologies to aid early detection of cancer. This is one strand of the Office for Life Sciences’ (OLS) Cancer Programme, which supports the development of technologies that enable earlier, more effective cancer diagnosis and improved treatment. OLS is a joint Department of Health and Social Care (DHSC) and Department for Science Innovation and Technology (DSIT) unit, ensuring both departments are involved in this work.
Asked by: Paulette Hamilton (Labour - Birmingham Erdington)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what proportion of pancreatic cancers were diagnosed at an early stage in the most recent year for which information is available.
Answered by Andrew Stephenson
Latest figures from NHS Digital for cancers diagnosed between January and December 2021 show that 25% of pancreatic cancers were diagnosed at Stage 1 and 2.
NHS England is developing new dedicated urgent diagnostic pathways for these patients so that every cancer patient with concerning, but non-specific symptoms, gets the right tests at the right time in as few visits as possible. There are now 113 of these pathways live, which are seeing more than 5,500 patients per month.
NHS England is also providing a route into pancreatic cancer surveillance for those at high-risk due to family history or at-risk genetic mutations and have formed an expert group to consider a pathway for Hepato-Pancreato-Biliary cancers, including pancreatic cancer.
NHS England is funding a new audit into pancreatic cancer to increase the consistency of access to treatments and to stimulate improvements in cancer treatment and outcomes for patients. The Royal College of Surgeons began work on this audit in October 2022 and the first report is expected in October 2024. In addition to this, the Getting it Right First-Time team in NHS England is undertaking a deep dive into pancreatic cancer, which will highlight actions National Health Service providers need to take to improve services, as well as gathering examples of good practice to share.
Asked by: Paulette Hamilton (Labour - Birmingham Erdington)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to increase the rate of diagnosis of pancreatic cancers at an early stage.
Answered by Andrew Stephenson
Latest figures from NHS Digital for cancers diagnosed between January and December 2021 show that 25% of pancreatic cancers were diagnosed at Stage 1 and 2.
NHS England is developing new dedicated urgent diagnostic pathways for these patients so that every cancer patient with concerning, but non-specific symptoms, gets the right tests at the right time in as few visits as possible. There are now 113 of these pathways live, which are seeing more than 5,500 patients per month.
NHS England is also providing a route into pancreatic cancer surveillance for those at high-risk due to family history or at-risk genetic mutations and have formed an expert group to consider a pathway for Hepato-Pancreato-Biliary cancers, including pancreatic cancer.
NHS England is funding a new audit into pancreatic cancer to increase the consistency of access to treatments and to stimulate improvements in cancer treatment and outcomes for patients. The Royal College of Surgeons began work on this audit in October 2022 and the first report is expected in October 2024. In addition to this, the Getting it Right First-Time team in NHS England is undertaking a deep dive into pancreatic cancer, which will highlight actions National Health Service providers need to take to improve services, as well as gathering examples of good practice to share.
Asked by: Mark Hendrick (Labour (Co-op) - Preston)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help reduce the time taken to diagnose pancreatic cancer.
Answered by Andrew Stephenson
NHS England is delivering a range of interventions that are expected to increase early diagnosis and improve outcomes for those with pancreatic cancer. This includes providing a route into pancreatic cancer surveillance for those at inherited high-risk to identify lesions before they develop into cancer and diagnose cancers sooner; creating new pathways to support faster referral routes for people with non-specific symptoms that could be linked to a range of cancer types; and increasing direct access for general practitioners to diagnostic tests.
NHS England is funding a new audit into pancreatic cancer, the aim of which is to provide regular and timely evidence to cancer service providers of where patterns of care in England may vary, to increase the consistency of access to treatments and to stimulate improvements in cancer treatment and outcomes for patients. The Royal College of Surgeons began work on this audit in October 2022 and a scoping exercise in consultation with key stakeholders has taken place to shape the direction of the audit. The first report is expected in October 2024.
In addition, the Getting It Right First Time team in NHS England is undertaking a deep dive into pancreatic cancer, which will highlight actions National Health Service providers need to take to improve services, as well as gathering examples of good practice to share.
Jul. 05 2010
Source Page: Guidance on Commissioning Cancer Services Improving Outcomes in Upper Gastro-intestinal Cancers. The Manual. 102 p.Found: Guidance on Commissioning Cancer Services Improving Outcomes in Upper Gastro-intestinal Cancers.
Asked by: Claire Hanna (Social Democratic & Labour Party - Belfast South and Mid Down)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment she has given to the potential merits of increasing the level of funding for research into (a) pancreatic cancer and (b) other cancers with lower survival rates.
Answered by Andrew Stephenson
The Government is proud to invest £1.3 billion per year on health research through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was over £121.8 million for 2022/23, and more is spent on cancer than any other disease group. Our investments in cancer, including rare and less survivable cancers such as pancreatic cancer, are pivotal to informing efforts to improve cancer prevention, treatment, and care.
As part of our commitment to driving more and better research into less survivable cancers, the Government awarded £2 million to new interdisciplinary research teams tackling hard to treat cancers via the Medical Research Council’s two-day cancer sandpit strategic funding opportunity in 2023, which focused on technological innovation for understanding cancers, including pancreatic cancer, with the poorest survival rates.
The NIHR continues to encourage and welcome applications for research into any aspect of human health, including pancreatic cancer and other cancers with lower survival rates. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality, rather than against specific disease funding allocations. We would welcome more applications from researchers working on pancreatic cancer prevention, treatment, and care.